GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » Forward PE Ratio

Actinogen Medical (ASX:ACW) Forward PE Ratio : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical Forward PE Ratio?

Actinogen Medical's Forward PE Ratio for today is 0.00.

Actinogen Medical's PE Ratio without NRI for today is 0.00.

Actinogen Medical's PE Ratio for today is 0.00.


Actinogen Medical Forward PE Ratio Historical Data

The historical data trend for Actinogen Medical's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical Forward PE Ratio Chart

Actinogen Medical Annual Data
Trend 2022-10
Forward PE Ratio
25.97

Actinogen Medical Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Actinogen Medical's Forward PE Ratio

For the Biotechnology subindustry, Actinogen Medical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's Forward PE Ratio falls into.



Actinogen Medical Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Actinogen Medical  (ASX:ACW) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Actinogen Medical Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical (ASX:ACW) Business Description

Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical (ASX:ACW) Headlines

From GuruFocus

Stocks That Are Making A Good Come Back

By reports.droy reports.droy 03-10-2015

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish 10-13-2014